GenSci144 Tablets Phase I Clinical Trial

This study is a Phase I single ascending dose clinical trial in which healthy adult volunteers were administered single oral doses of GenSci144 tablets at different levels. It was conducted using a randomized, double-blind, placebo-controlled design, primarily to evaluate the drug's safety and tolerability, while also exploring its pharmacokinetic and pharmacodynamic characteristics in the body, providing a basis for subsequent clinical use in the treatment of phenylketonuria.

NCT Number	NCT07685210
Lead Sponsor	Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions	Phenylketonuria
Enrollment	48 participants
Start Date	2026-06-22
Primary Completion	2026-09 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-06